KeyNeurotek AG Strengthens Finance and Clinical Development Management
KeyNeurotek AG, a biotechnology company focused on the development and marketing of drugs against degenerative disorders of the central nervous system (CNS) is announcing the enforcement of its management board. In addition to Dr. Frank Striggow (CEO), Hong Thieu has been appointed Chief Financial Officer. Hong Thieu brings several years of biotech industry expertise, in particular competence in growth financing. During his career he has worked with several growth-oriented companies, accompanying financing rounds and IPOs. In his last position Hong Thieu was Vice President Corporate Affairs at Berlin-based listed biotech company Epigenomics AG.
In addition, KeyNeurotek announces the enforcement of its management through the appointment of Orell Mielke, MD, as Vice President Clinical Research and Development. Dr. Mielke is a neurologist bringing several years of professional experience in drug development and registration to the team. In his latest position Dr. Mielke was Associate Medical Director at clinical research organization Parexel International. His experience in brain disorders will be an ideal complement to the company's competence portfolio.
KeyNeurotek AG has several product candidates in various preclinical and clinical development stages. Its lead product KN 38-7271, a cannabinoid receptor agonist, is scheduled to enter a Phase II study in patients with traumatic brain injury soon. "With these appointments we are consequently following the path towards becoming a leading CNS drug development company. With their proven and complementary expertise Hong Thieu and Dr. Mielke will be of great support to achieve this goal", said Dr. Frank Striggow, CEO of KeyNeurotek AG.
Other news from the department people
